It has been reported that targeting PD-1, PD-L1 or CTLA-4 may provide different outcomes in gastric cancer [65] and hepatocellular carcinoma [66]; thus, hypothesizing whether the application of different ICIs was associated with different efficacies in patients with GI cancer. Here, CD274 is linked to hepatocellular carcinoma.